Cargando…

Use of letermovir in umbilical cord blood transplantation based on risk scores

Detalles Bibliográficos
Autores principales:	Rivera Franco, Monica M., Rafii, Hanadi, Volt, Fernanda, Kenzey, Chantal, Cappelli, Barbara, Scigliuolo, Graziana Maria, Rocha, Vanderson, Raus, Nicole, Dalle, Jean-Hugues, Chevallier, Patrice, Robin, Marie, Rubio, Marie Thérèse, Ruggeri, Annalisa, Gluckman, Eliane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424128/ https://www.ncbi.nlm.nih.gov/pubmed/37276384 http://dx.doi.org/10.1182/bloodadvances.2023010573

Ejemplares similares

Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe
por: Rafii, Hanadi, et al.
Publicado: (2022)

Unrelated Donor Cord Blood Transplantation in Children: Lessons Learned Over 3 Decades
por: Kurtzberg, Joanne, et al.
Publicado: (2023)

Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies
por: Fatobene, Giancarlo, et al.
Publicado: (2023)

HLA haplotype frequencies and diversity in patients with hemoglobinopathies
por: Scigliuolo, Graziana M., et al.
Publicado: (2023)

PB1752: ANALYSIS OF HLA-PEPTIDE BINDING POCKETS IN PATIENTS WITH ACUTE LEUKEMIA UNDERGOING UMBILICAL CORD BLOOD TRANSPLANTATION
por: Boukouaci, W., et al.
Publicado: (2022)

Use of the HLA-B leader to optimize cord blood transplantation
por: Petersdorf, Effie W., et al.
Publicado: (2020)

Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC)
por: Rafii, Hanadi, et al.
Publicado: (2021)

Possible Effect of the use of Mesenchymal Stromal Cells in the Treatment of Autism Spectrum Disorders: A Review
por: Tamouza, Ryad, et al.
Publicado: (2022)

Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC)
por: Rafii, Hanadi, et al.
Publicado: (2021)

Polymorphisms in Inflammatory Genes Modulate Clinical Complications in Patients With Sickle Cell Disease
por: Tozatto-Maio, Karina, et al.
Publicado: (2020)

Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks
por: Rafii, Hanadi, et al.
Publicado: (2017)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

1897. Letermovir Salvage for Complicated Cases of Resistant CMV
por: Turner, Nicholas, et al.
Publicado: (2018)

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis
por: Hedvat, Jason, et al.
Publicado: (2019)

Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT
por: Baron, Frédéric, et al.
Publicado: (2017)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient
por: Koepf, Uta S, et al.
Publicado: (2020)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
por: Giménez, Estela, et al.
Publicado: (2023)

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency
por: Popping, Stephanie, et al.
Publicado: (2019)

A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome
por: Shekhovtsova, Zhanna, et al.
Publicado: (2017)

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
por: Martino, Massimo, et al.
Publicado: (2021)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
por: El Helou, Guy, et al.
Publicado: (2019)

Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting
por: Marzolini, Maria A. V., et al.
Publicado: (2021)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

215b. Real-World Experience of Letermovir Use at an Academic Transplant Center
por: Ryu, HaYoung, et al.
Publicado: (2022)

2740. Letermovir for the Prevention and Treatment of Cytomegalovirus Infection in Solid Organ Transplant Recipients
por: Xhemali, Xhilda, et al.
Publicado: (2023)

Improving Engraftment and Immune Reconstitution in Umbilical Cord Blood Transplantation
por: Danby, Robert, et al.
Publicado: (2014)

Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)
por: Pochon, Cécile, et al.
Publicado: (2021)

Ganciclovir/letermovir: Rebound Cytomegalovirus hepatitis, acquired resistance to ganciclovir and nephrotoxicity: case report
Publicado: (2020)

571. “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation
por: Loecher, Alyssa M, et al.
Publicado: (2020)

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients
por: Santos Bravo, Marta, et al.
Publicado: (2022)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
por: Baron, Frédéric, et al.
Publicado: (2019)

Isavuconazole/letermovir/remdesivir: Drug-induced liver injury and off-label use: case report
Publicado: (2021)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

OUTCOMES OF UCB TRANSPLANTATION ARE COMPARABLE IN FLT3+ AML: RESULTS OF CIBMTR, EUROCORD AND EBMT COLLABORATIVE ANALYSIS
por: Ustun, Celalettin, et al.
Publicado: (2017)

Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
por: Shigle, Terri Lynn, et al.
Publicado: (2020)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vo9i13tttureq3o9dm11kdl1r4